The Quantellect read.As of Nov 19, 2026, 4 active firms cover MediciNova Inc: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $6.00 to $10.00, a moderate spread. The average target of $7.75 sits 483% above the current $1.33. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.47 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$7.75
+482.7% upside
Average target across 4 active firms as of Nov 19, 2026 vs $1.33 current
Highest Target$10.00
Average Target$7.75
Lowest Target$6.00
Detailed analyst forecasts for MNOV
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate MNOV a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MNOV EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.08 – $-0.08 · 1 analysts · +60% YoY
Next period, 1 analysts expect MediciNova Inc to earn $-0.08 a share (range $-0.08 – $-0.08), versus $-0.05 a year earlier. Full-year consensus is $-0.21, growing to $-0.47 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $1.0M, rising to $0 next year.
Top analysts covering MediciNova Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MNOV.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$5.00+275.9% to target
Overall win rate
49%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$9.00+576.7% to target
Overall win rate
22%
+ Follow
#3
Jason McCarthy
Maxim Group · Rank #567
Buy
$6.00+351.1% to target
Overall win rate
30%
+ Follow
#4
Boobalan Pachaiyappan
Roth Capital
Buy
$6.00+351.1% to target
Coverage
—
+ Follow
#5
LE
Lander Egaña Gorroño
HC Wainwright & Co.
Buy
$10.00+651.9% to target
Coverage
—
+ Follow
MNOV stock forecast FAQ
What is MNOV's average 12-month price target?+
The 4 active firms with a live target average $7.75 for MediciNova Inc over the next 12 months, ranging from a $10.00 high to a $6.00 low, as of Nov 19, 2026.
Is MNOV stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MNOV?+
The Street-high target is $10.00 (HC Wainwright & Co.), and the Street-low is $6.00 (Roth Capital). The average of all 4 active-firm targets is $7.75.
How many active Wall Street firms cover MNOV?+
4 active firms have a recognized rating on MediciNova Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MNOV?+
Among analysts who currently cover MNOV, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $5.00 target.
What is MediciNova Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.08 – $-0.08) across 1 analysts. Full-year EPS is projected at $-0.21, rising to $-0.47 the following year.
How much revenue is MediciNova Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $1.0M, growing to $0 next year.
Have analysts been upgrading or downgrading MNOV lately?+
As of Nov 19, 2026, 4 of 4 active firms rate MNOV a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MNOV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.